ReviewJournal of translational medicine2021
Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target.
Review in Journal of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 1 synthesis or guideline pooled it, 154 citations in OpenAlex.
- Emerging Perspectives of Bone Metastasis in Hepatocellular Carcinoma.Frontiers in oncology · 2022Pooled it
- Unveiling potential natural promoters of calcium oxalate kidney stones in the urine via anion-exchange chromatography, crystal assays, and proteomics.Molecular and cellular biochemistry · 2026Article
- Notch signaling regulates the secretion of pro-metastatic factors in extracellular vesicles in liposarcoma.Cancer letters · 2026Article
- Expression, Localization and Actions of Galectin-3: Implications in the Pathophysiology and Therapy of Cardiovascular Disease.International journal of molecular sciences · 2026Review
- Predicting isocitrate dehydrogenase mutation status in acute myeloid leukemia from gene expression profiles by machine learning.NAR genomics and bioinformatics · 2026Article
- Exosome-mediated miR-4660 delivery inhibits OPN promoted hepatoma cells aggression through targeting LGALS3BP.Journal of cell communication and signaling · 2026Article
- Targeting KITENIN signaling in cancer progression and therapeutic resistance: mechanistic insights and future directions.Cancer cell international · 2026Review
- Phaeochromocytomas and paragangliomas harbour tumour-initiating SOX2+ stem cells.Endocrine-related cancer · 2026Article
- Investigation of Antitumor Activity of Modified Citrus Pectin: Oral and Intravenous Administration Assessed via Molecular Imaging.Biomacromolecules · 2026Article
- The Galectin-3-binding protein promotes angiogenesis in pancreatic cancer via simultaneous upregulation of VEGFA and direct HUVEC activation mediated by and VAMP5-STAT3.Cell communication and signaling : CCS · 2026Article
- Distinct Proteomic and Glycosylation Signatures Differentiate A549 Tumor and BEAS-2B Nontumor Cell Line-Derived Small Extracellular Vesicles.Molecular & cellular proteomics : MCP · 2026Article
- Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker.Molecular oncology · 2026Article
- Comprehensive prognostic and immune infiltration assessment of LGALS3BP in pan-cancer patients.Discover oncology · 2026Article
- Ab-SELDON: Leveraging Diversity Data for an Efficient Automated Computational Pipeline for Antibody Design.Journal of chemical information and modeling · 2026Article
- LGALS3BP Induces Insulin Resistance via TLR2-IKKα/β Pathway-Mediated IRS1 Serine Phosphorylation.Endocrinology and metabolism (Seoul, Korea) · 2026Article
- Blood DNA methylation-predicted plasma protein levels and colorectal cancer survival.Clinical epigenetics · 2026Article
- Proteomic analysis revealed the potential usefulness of faecal extracellular vesicles in colorectal cancer diagnosis.Scientific reports · 2026Article
- Article
- Development and Validation of an HPLC-MS/MS Method for Determining BMS-1166, GB-1107, and Enzalutamide in Rat Plasma and Its Application to Pharmacokinetic Studies.Drug design, development and therapy · 2026Article
- Distinctive features of cancer-associated fibroblasts expressing CD105, a novel biomarker for bone metastasis, in early-stage invasive ductal breast cancer.Frontiers in endocrinology · 2026Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a secreted, hyperglycosylated protein expressed by the majority of human cells. It was first identified as cancer and metastasis associated protein, while its role in innate immune response upon viral infection remains still to be clarified. Since its discovery dated in early 90 s, a large body of literature has been accumulating highlighting both a prognostic and functional role for LGALS3BP in cancer. Moreover, data from our group and other have strongly suggested that this protein is enriched in cancer-associated extracellular vesicles and may be considered a promising candidate for a targeted therapy in LGALS3BP positive cancers. Here, we extensively reviewed the literature relative to LGALS3BP role in cancer and its potential value as a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.